HCW Biologics, Inc. (HCWB)

NASDAQ: HCWB · IEX Real-Time Price · USD
2.15
+0.01 (0.47%)
At close: Nov 29, 2022 3:55 PM
2.14
-0.01 (-0.47%)
After-hours: Nov 29, 2022 4:00 PM EST
0.47%
Market Cap 76.77M
Revenue (ttm) n/a
Net Income (ttm) -11.70M
Shares Out 35.84M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,066
Open 2.12
Previous Close 2.14
Day's Range 2.12 - 2.16
52-Week Range 1.76 - 3.32
Beta n/a
Analysts Buy
Price Target 7.14 (+232.1%)
Earnings Date Nov 11, 2022

About HCWB

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical ... [Read more]

Industry Biotechnology
IPO Date Jul 20, 2021
Employees 44
Stock Exchange NASDAQ
Ticker Symbol HCWB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for HCWB stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 232.09% from the latest price.

Price Target
$7.14
(232.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial...

Presentation includes data on safety and dosage escalation and immune system reaction to HCW9218

3 weeks ago - GlobeNewsWire

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing no...

3 weeks ago - GlobeNewsWire

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are ...

US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: QUOTSMSIWLMS
2 months ago - Benzinga

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: CASIHSDT
3 months ago - Benzinga

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing no...

3 months ago - GlobeNewsWire

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product...

3 months ago - GlobeNewsWire

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies ...

6 months ago - GlobeNewsWire

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherap...

6 months ago - GlobeNewsWire

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform ...

Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells  Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy

6 months ago - GlobeNewsWire

HCW Biologics' CEO Hing C. Wong, Ph.D.

Preclinical data for lead investigational drug, HCW9218,  in treatment of therapy-induced senescence in cancer

7 months ago - GlobeNewsWire

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023

8 months ago - GlobeNewsWire

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat”

8 months ago - GlobeNewsWire

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors wi...

10 months ago - Benzinga

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in...

UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers UM cleared to proceed with clinical trial to eva...

10 months ago - GlobeNewsWire

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated th...

10 months ago - Benzinga

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects ...

Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular Therapy Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular Therapy

10 months ago - GlobeNewsWire

HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conf...

A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218 A Novel Platform to Create Multi-Functional Immunother...

10 months ago - GlobeNewsWire

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022

MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he...

10 months ago - GlobeNewsWire

HCW Biologics' Founder and CEO Dr. Hing C. Wong Named Weaver H.

Award recognizes extraordinary contributions to the growth of life sciences Award recognizes extraordinary contributions to the growth of life sciences

11 months ago - GlobeNewsWire

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel...

1 year ago - GlobeNewsWire

HCWB Stock: The Big FDA News That Has HCW Biologics Booming Today

HCW Biologics (HCWB) stock is rocketing higher on Thursday thanks to a recent update from the U.S. Food and Drug Administration (FDA). The post HCWB Stock: The Big FDA News That Has HCW Biologics Boomin...

1 year ago - InvestorPlace

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancre...

Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company's lead product candidate, in refractory, advanced/metastatic pancreatic cancer

1 year ago - GlobeNewsWire

HCW Biologics Announces Appointment of Two New Members to Board of Directors

New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and Governance New Members Add Depth to Board with Experience in Strategic Transactions, Strat...

1 year ago - GlobeNewsWire

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctiona...

Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform

1 year ago - GlobeNewsWire

HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein ...

TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells

1 year ago - GlobeNewsWire